CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
This section weighs security guarantees across Pow and Pos, helping readers decide which consensus offers stronger protections for their needs.
24,327 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Purchase applications rose 7% week over week and 17% year over year, even as mortgage rates hover near cycle highs. A...
As markets wobble, traders watch RSI and other momentum tools to spot oversold stocks. This piece explains what overs...
The S&P 500 is doing something unseen more in modern markets, hinting at far-reaching implications for portfolios. Hi...
In mid-2026 markets, Dave Ramsey endorses a disciplined $5,000 index-fund starting point over chasing a single-stock ...
Tuesday brought a notable standout in the banking space as JPMorgan Chase topped market momentum. This piece breaks d...
When a company’s founder and CEO sells a chunk of stock, investors want to know what it means for future performance....
In June 2026, Bitcoin traders face a new threat: boredom. CryptoQuant sees a protracted lull in demand as the real ri...
As markets swing in June 2026, retirees with over million are shifting from pure cash to a five-year ladder that blen...
HomeServices of America and Douglas Elliman scored legal wins this week as they push forward with nationwide homebuye...
A Vesta director recently sold roughly $203,000 worth of stock while the company’s shares have risen about 25% over t...
Mega IPOs grab headlines and spark fears of a market crash. This article breaks down the data, weighs the odds, and s...